Glucokinase activators in diabetes management
暂无分享,去创建一个
[1] Antonio Ceriello,et al. Postprandial hyperglycaemia and cardiovascular complications of diabetes: an update. , 2006, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[2] R. Holman,et al. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .
[3] M. Fantone,et al. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus , 1997, Diabetes Care.
[4] F M Matschinsky,et al. Familial hyperinsulinism caused by an activating glucokinase mutation. , 1998, The New England journal of medicine.
[5] Neil R. Powe,et al. Meta-Analysis: Glycosylated Hemoglobin and Cardiovascular Disease in Diabetes Mellitus , 2004, Annals of Internal Medicine.
[6] M. Magnuson,et al. The network of glucokinase-expressing cells in glucose homeostasis and the potential of glucokinase activators for diabetes therapy. , 2006, Diabetes.
[7] A. Gloyn,et al. Glucokinase and the Regulation of Blood Sugar , 2004 .
[8] F. Bosch,et al. Correction of diabetic alterations by glucokinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[9] K. Narayan,et al. Trends in cardiovascular complications of diabetes. , 2005, JAMA.
[10] N. Day,et al. Association of Hemoglobin A1c with Cardiovascular Disease and Mortality in Adults: The European Prospective Investigation into Cancer in Norfolk , 2004, Annals of Internal Medicine.
[11] V. Routh,et al. Glucokinase is the likely mediator of glucosensing in both glucose-excited and glucose-inhibited central neurons. , 2002, Diabetes.
[12] P. Cryer. Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A Consensus Statement From the American Diabetes Association and the European Association for the Study of Diabetes , 2007, Diabetes Care.
[13] H. Aburatani,et al. Glucokinase and IRS-2 are required for compensatory beta cell hyperplasia in response to high-fat diet-induced insulin resistance. , 2007, The Journal of clinical investigation.
[14] Klaus Brusgaard,et al. The second activating glucokinase mutation (A456V): implications for glucose homeostasis and diabetes therapy. , 2002, Diabetes.
[15] Robert A. Rizza,et al. β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes , 2003, Diabetes.
[16] K. Nakanishi,et al. Characterization of dihydro-A2PE: an intermediate in the A2E biosynthetic pathway. , 2007, Biochemistry.
[17] S. Nissen,et al. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.
[18] F. Reimann,et al. Glucose-sensing in glucagon-like peptide-1-secreting cells. , 2002, Diabetes.
[19] Teven,et al. MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .
[20] G. Dohm,et al. Liver Glucokinase: Decreased Activity in Patients with Type II Diabetes , 1995, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.
[21] V. Routh,et al. Anatomy, Physiology and Regulation of Glucokinase as a Brain Glucosensor , 2004 .
[22] C. Newgard,et al. Evidence for a Role of Glucose-induced Translocation of Glucokinase in the Control of Hepatic Glycogen Synthesis* , 1996, The Journal of Biological Chemistry.
[23] F M Matschinsky,et al. A Lesson in Metabolic Regulation Inspired by the Glucokinase Glucose Sensor Paradigm , 1996, Diabetes.
[24] L. Rossetti,et al. Hypothalamic sensing of fatty acids , 2005, Nature Neuroscience.
[25] D. Nathan. Finding new treatments for diabetes--how many, how fast... how good? , 2007, The New England journal of medicine.
[26] I. Gabriely,et al. Fructose improves the ability of hyperglycemia per se to regulate glucose production in type 2 diabetes. , 2002, Diabetes.
[27] A. Cornish-Bowden,et al. Kinetic evidence for a 'mnemonical' mechanism for rat liver glucokinase. , 1977, The Biochemical journal.
[28] M. Tschöp,et al. Two birds with one stone: novel glucokinase activator stimulates glucose-induced pancreatic insulin secretion and augments hepatic glucose metabolism. , 2003, Molecular interventions.
[29] R. M. Shepherd,et al. Hyperinsulinism in infancy: from basic science to clinical disease. , 2004, Physiological reviews.
[30] J. Shaw,et al. Follow-up report on the diagnosis of diabetes mellitus. , 2003, Diabetes care.
[31] S. Genuth,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.
[32] Jian Zhang,et al. Conformational transition pathway in the allosteric process of human glucokinase , 2006, Proceedings of the National Academy of Sciences.
[33] B. Zinman,et al. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy , 2009, Diabetes Care.
[34] J. Marcinkeviciene,et al. A pre-steady state analysis of ligand binding to human glucokinase: evidence for a preexisting equilibrium. , 2007, Biochemistry.
[35] S. Saydah,et al. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. , 2004, JAMA.
[36] H. Najafi,et al. Glucose regulates glucokinase activity in cultured islets from rat pancreas. , 1990, The Journal of biological chemistry.
[37] M. Magnuson,et al. Effects of altered glucokinase gene copy number on blood glucose homoeostasis. , 1997, Biochemical Society transactions.
[38] Antonio Ceriello,et al. Impaired glucose tolerance and cardiovascular disease: the possible role of post-prandial hyperglycemia. , 2004, American heart journal.
[39] D. Schmoll,et al. The role of glucose 6‐phosphate in mediating the effects of glucokinase overexpression on hepatic glucose metabolism , 2006, The FEBS journal.
[40] P. Raskin,et al. Report of the expert committee on the diagnosis and classification of diabetes mellitus. , 1999, Diabetes care.
[41] D. Smith,et al. Effect of high‐fat diet on glucose homeostasis and gene expression in glucokinase knockout mice , 2008, Diabetes, obesity & metabolism.
[42] E. Feskens,et al. Glucose tolerance and mortality: comparison of WHO and American Diabetic Association diagnostic criteria , 1999, The Lancet.
[43] M. Jensen,et al. Type 2 diabetes impairs splanchnic uptake of glucose but does not alter intestinal glucose absorption during enteral glucose feeding: additional evidence for a defect in hepatic glucokinase activity. , 2001, Diabetes.
[44] R. Rizza,et al. Insulin dose-response curves for stimulation of splanchnic glucose uptake and suppression of endogenous glucose production differ in nondiabetic humans and are abnormal in people with type 2 diabetes. , 2004, Diabetes.
[45] S. Bonner-Weir,et al. A dominant role for glucose in beta cell compensation of insulin resistance. , 2007, The Journal of clinical investigation.
[46] A. Hattersley,et al. Insights into the biochemical and genetic basis of glucokinase activation from naturally occurring hypoglycemia mutations. , 2003, Diabetes.
[47] E. Eschwège,et al. Evaluation of risk factors for development of complications in Type II diabetes in Europe , 2002, Diabetologia.
[48] M. Magnuson,et al. Analysis of upstream glucokinase promoter activity in transgenic mice and identification of glucokinase in rare neuroendocrine cells in the brain and gut. , 1994, The Journal of biological chemistry.
[49] H. Huopio,et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. , 2004, Diabetes.
[50] D. Nettleton,et al. Glucose-induced conformational changes in glucokinase mediate allosteric regulation: transient kinetic analysis. , 2006, Biochemistry.
[51] J. Gromada,et al. A novel glucokinase activator modulates pancreatic islet and hepatocyte function. , 2005, Endocrinology.
[52] M. Kaleko,et al. Phenotypic correction of diabetic mice by adenovirus-mediated glucokinase expression. , 2001, Diabetes.
[53] Teruyuki Nishimura,et al. Structural basis for allosteric regulation of the monomeric allosteric enzyme human glucokinase. , 2004, Structure.
[54] Scott Boyd,et al. Discovery, synthesis and biological evaluation of novel glucokinase activators. , 2005, Bioorganic & medicinal chemistry letters.
[55] James P. Smith. Nature and causes of trends in male diabetes prevalence, undiagnosed diabetes, and the socioeconomic status health gradient , 2007, Proceedings of the National Academy of Sciences.
[56] A. Molven,et al. Permanent neonatal diabetes caused by glucokinase deficiency: inborn error of the glucose-insulin signaling pathway. , 2003, Diabetes.
[57] D. Piston,et al. Cell-specific Expression and Regulation of a Glucokinase Gene Locus Transgene* , 1997, The Journal of Biological Chemistry.
[58] B. Zinman,et al. Earlier intervention in type 2 diabetes: The case for achieving early and sustained glycaemic control , 2005, International journal of clinical practice.
[59] M. Coghlan,et al. Stimulation of hepatocyte glucose metabolism by novel small molecule glucokinase activators. , 2004, Diabetes.
[60] R. Marfella,et al. Effect of weight loss on cardiac synchronization and proinflammatory cytokines in premenopausal obese women. , 2004, Diabetes care.
[61] F. Matschinsky,et al. Immunohistochemical Evidence for the Presence of Glucokinase in the Gonadotropes and Thyrotropes of the Anterior Pituitary Gland of Rat and Monkey , 2007, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[62] J. Lau,et al. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. , 2007, JAMA.
[63] M. Hanefeld,et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, 11-year follow-up , 1996, Diabetologia.
[64] V. Routh,et al. Neuronal glucosensing: what do we know after 50 years? , 2004, Diabetes.
[65] S. Yusuf,et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. , 1999, Diabetes care.
[66] J. Grimsby,et al. Small molecule glucokinase activators as glucose lowering agents: a new paradigm for diabetes therapy. , 2006, Current medicinal chemistry.
[67] W. Cefalu,et al. Glycemic control and cardiovascular disease--should we reassess clinical goals? , 2005, The New England journal of medicine.
[68] W C Willett,et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. , 2001, Archives of internal medicine.
[69] A. Kadotani,et al. An Allosteric Activator of Glucokinase Impairs the Interaction of Glucokinase and Glucokinase Regulatory Protein and Regulates Glucose Metabolism* , 2006, Journal of Biological Chemistry.
[70] S. Genuth. Lowering the criterion for impaired fasting glucose is in order. , 2003, Diabetes care.
[71] M. Magnuson,et al. Concordant Glucose Induction of Glucokinase, Glucose Usage, and Glucose-Stimulated Insulin Release in Pancreatic Islets Maintained in Organ Culture , 1992, Diabetes.
[72] V. Routh,et al. Insulin activates ATP-sensitive K+ channels in hypothalamic neurons of lean, but not obese rats , 2000, Nature Neuroscience.
[73] Giuseppe d'Annunzio,et al. Insights into the Structure and Regulation of Glucokinase from a Novel Mutation (V62M), Which Causes Maturity-onset Diabetes of the Young* , 2005, Journal of Biological Chemistry.
[74] E. Bonora,et al. Postprandial blood glucose as a risk factor for cardiovascular disease in Type II diabetes: the epidemiological evidence , 2001, Diabetologia.
[75] J. Beckmann,et al. Close linkage of glucokinase locus on chromosome 7p to early-onset non-insulin-dependent diabetes mellitus , 1992, Nature.
[76] M. Jensen,et al. Effects of type 2 diabetes on the ability of insulin and glucose to regulate splanchnic and muscle glucose metabolism: evidence for a defect in hepatic glucokinase activity. , 2000, Diabetes.
[77] M. Hanefeld,et al. Prandial hyperglycemia: is it important to track and treat? , 2005, Current diabetes reports.
[78] V. Basevi. Standards of medical care in diabetes--2007. , 2009, Diabetes care.
[79] P. Iynedjian. Mammalian glucokinase and its gene. , 1993, The Biochemical journal.
[80] S. Wild,et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. , 2004, Diabetes care.
[81] A. Treloar,et al. Expression of Human Hepatic Glucokinase in Transgenic Mice Liver Results in Decreased Glucose Levels and Reduced Body Weight , 1997, Diabetes.
[82] T. Fujita,et al. Glucokinase is located in secretory granules of pancreatic D‐cells , 1997, FEBS letters.
[83] B. Zinman,et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. , 2005, The New England journal of medicine.
[84] M. Nawano,et al. Glucokinase-activating ureas. , 2005, Bioorganic & medicinal chemistry letters.
[85] Norman Fleischer,et al. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. , 1993 .
[86] R. DeFronzo,et al. Pathogenesis of NIDDM: A Balanced Overview , 1992, Diabetes Care.
[87] Robert M. Anderson,et al. Prevention or delay of type 2 diabetes. , 2004, Diabetes care.
[88] M. Cárdenas. Glucokinase: Its Regulation and Role in Liver Metabolism , 1995 .
[89] C. Newgard,et al. Metabolic impact of glucokinase overexpression in liver: lowering of blood glucose in fed rats is accompanied by hyperlipidemia. , 1999, Diabetes.
[90] J. Grimsby,et al. Targeting glucokinase activation for the treatment of type 2 diabetes--a status review. , 2005, Current opinion in drug discovery & development.
[91] R. Printz,et al. Glucokinase activator PSN-GK1 displays enhanced antihyperglycaemic and insulinotropic actions , 2007, Diabetologia.
[92] M. Magnuson,et al. Effects of Glucose on Insulin Secretion, Glucokinase Activity, and Transgene Expression in Transgenic Mouse Islets Containing an Upstream Glucokinase Promoter-Human Growth Hormone Fusion Gene , 1994, Diabetes.
[93] Craig S Donald,et al. Design of a potent, soluble glucokinase activator with excellent in vivo efficacy. , 2006, Bioorganic & medicinal chemistry letters.
[95] J. Grippo,et al. Glucokinase gene locus transgenic mice are resistant to the development of obesity-induced type 2 diabetes. , 2001, Diabetes.
[96] H. Gerstein. Glycosylated Hemoglobin: Finally Ready for Prime Time as a Cardiovascular Risk Factor , 2004, Annals of Internal Medicine.
[97] J. Grippo,et al. Allosteric Activators of Glucokinase: Potential Role in Diabetes Therapy , 2003, Science.
[98] V. Routh,et al. Glucokinase is a critical regulator of ventromedial hypothalamic neuronal glucosensing. , 2006, Diabetes.
[99] C. Bailey,et al. Oral antidiabetic agents: current role in type 2 diabetes mellitus. , 2005, Drugs.
[100] N. Clark,et al. Standards of Medical Care in Diabetes: Response to Power , 2006 .
[101] C. Allott,et al. Predictive blood glucose lowering efficacy by Glucokinase activators in high fat fed female Zucker rats , 2006, British journal of pharmacology.
[102] M. Magnuson,et al. Effects of Increased Glucokinase Gene Copy Number on Glucose Homeostasis and Hepatic Glucose Metabolism* , 1997, The Journal of Biological Chemistry.
[103] S. Bonner-Weir,et al. A dominant role for glucose in β cell compensation of insulin resistance , 2007 .
[104] P. Froguel,et al. Impaired hepatic glycogen synthesis in glucokinase-deficient (MODY-2) subjects. , 1996, The Journal of clinical investigation.
[105] A. Cherrington,et al. Acute fructose administration improves oral glucose tolerance in adults with type 2 diabetes. , 2001, Diabetes care.
[106] Haiyan Wang,et al. Modulation of glucose responsiveness of insulinoma beta-cells by graded overexpression of glucokinase. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[107] O. Madsen,et al. The glucose sensor protein glucokinase is expressed in glucagon-producing alpha-cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[108] S. Khan,et al. Enhancing hepatic glycolysis reduces obesity: differential effects on lipogenesis depend on site of glycolytic modulation. , 2005, Cell metabolism.
[109] K. Clément,et al. Insulin secretory abnormalities in subjects with hyperglycemia due to glucokinase mutations. , 1994, The Journal of clinical investigation.
[110] J. Holst,et al. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of Type 2 diabetes? , 2004, Expert opinion on investigational drugs.
[111] R. Holman,et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study , 2000, BMJ : British Medical Journal.
[112] M. Magnuson,et al. Glucokinase Thermolability and Hepatic Regulatory Protein Binding Are Essential Factors for Predicting the Blood Glucose Phenotype of Missense Mutations* , 2007, Journal of Biological Chemistry.
[113] R. M. Shepherd,et al. Glucose-Dependent Modulation of Insulin Secretion and Intracellular Calcium Ions by GKA50, a Glucokinase Activator , 2007, Diabetes.
[114] Giovanni Pacini,et al. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. , 2005, Diabetes care.
[115] Michael J Pencina,et al. Increasing Cardiovascular Disease Burden Due to Diabetes Mellitus: The Framingham Heart Study , 2007, Circulation.
[116] N. Sanders,et al. Role of Neuronal Glucosensing in the Regulation of Energy Homeostasis , 2006, Diabetes.
[117] P. Tippett,et al. Observation of a kinetic slow transition in monomeric glucokinase. , 1990, Biochemistry.
[118] J. Shaw,et al. 1: Epidemiology and prevention of type 2 diabetes and the metabolic syndrome , 2003, The Medical journal of Australia.
[119] B. Ahrén. Vildagliptin: an inhibitor of dipeptidyl peptidase-4 with antidiabetic properties , 2006, Expert opinion on investigational drugs.
[120] J. Grippo,et al. Discovery and Actions of Glucokinase Activators , 2004 .